NAMS
Income statement / Annual
Last year (2025), NewAmsterdam Pharma Company NV's total revenue was $22.50 M,
a decrease of 50.61% from the previous year.
In 2025, NewAmsterdam Pharma Company NV's net income was -$203.82 M.
See NewAmsterdam Pharma Company NV,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$22.50 M |
$45.56 M |
$14.09 M |
$102.69 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$59.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$22.44 M
|
$45.56 M
|
$14.09 M
|
$102.69 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$141.83 M
|
$151.41 M
|
$159.42 M
|
$86.74 M
|
$28.97 M
|
$4.94 M
|
| General & Administrative Expenses |
$106.30 M
|
$70.45 M
|
$37.63 M
|
$19.51 M
|
$4.70 M
|
$1.68 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$977.00 K
|
$13.44 K
|
| Selling, General & Administrative Expenses |
$106.30 M
|
$70.45 M
|
$37.63 M
|
$19.51 M
|
$5.68 M
|
$1.69 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$326.00 K
|
$0.00
|
| Operating Expenses |
$248.13 M
|
$221.85 M
|
$197.06 M
|
$106.25 M
|
$34.98 M
|
$6.63 M
|
| Cost And Expenses |
$248.19 M
|
$221.85 M
|
$197.06 M
|
$106.25 M
|
$34.98 M
|
$6.63 M
|
| Interest Income |
$27.59 M
|
$16.88 M
|
$10.22 M
|
$0.00
|
$0.00
|
$851.00
|
| Interest Expense |
$0.00
|
$0.00
|
$6.80 M
|
$287.00 K
|
$411.00 K
|
$0.00
|
| Depreciation & Amortization |
$220.00 K
|
$113.00 K
|
$49.00 K
|
$9.00 K
|
$5.00 K
|
$1.22 K
|
| EBITDA |
-$242.33 M |
-$241.49 M |
-$176.86 M |
-$22.34 M |
-$41.37 M |
-$6.63 M |
| EBITDA Ratio |
-10.77
|
-5.3
|
-12.55
|
-0.22
|
0
|
0
|
| Operating Income Ratio |
-10.03
|
-3.87
|
-12.99
|
-0.03
|
0
|
0
|
| Total Other Income/Expenses Net |
$21.86 M
|
-$65.31 M
|
$6.06 M
|
-$19.08 M
|
-$6.81 M
|
-$390.91 K
|
| Income Before Tax |
-$203.82 M
|
-$241.60 M
|
-$176.91 M
|
-$22.63 M
|
-$41.79 M
|
-$7.02 M
|
| Income Before Tax Ratio |
-9.06
|
-5.3
|
-12.56
|
-0.22
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$1.00 K
|
$27.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$203.82 M
|
-$241.60 M
|
-$176.94 M
|
-$22.63 M
|
-$41.79 M
|
-$7.02 M
|
| Net Income Ratio |
-9.06
|
-5.3
|
-12.56
|
-0.22
|
0
|
0
|
| EPS |
-1.75 |
-2.56 |
-2.15 |
-1.19 |
-3.34 |
-1.15 |
| EPS Diluted |
-1.75 |
-2.56 |
-2.15 |
-1.19 |
-3.34 |
-1.15 |
| Weighted Average Shares Out |
$114.40 M
|
$94.36 M
|
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Weighted Average Shares Out Diluted |
$114.40 M
|
$94.36 M
|
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Link |
|
|
|
|
|
|
